Aprea Therapeutics, Inc. (APRE)
EBITDA Growth
11.16%
TTM · Period ending:
APRE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported11.16%period ending
Latest reported11.16%period ending
APRE TTM EBITDA YoY % (-164.48% → 11.16%)
Year-over-year change
High-resolution chart · PNG
APRE ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 11.1593% | |
| 15.1253% | |
| 2.7716% | |
| 3.4724% | |
| -7.1135% | |
| -10.67% | |
| 9.4071% | |
| -1.5269% | |
| 8.0662% | |
| 61.6947% | |
| 61.0472% | |
| 68.305% | |
| 70.328% | |
| 5.6059% | |
| 1.9182% | |
| 4.4378% | |
| -1.4548% | |
| 30.9592% | |
| 28.9182% | |
| 17.1549% | |
| 2.6401% | |
| -29.1963% | |
| -64.4972% | |
| -136.9078% | |
| -164.4839% |